An Integrated mHealth App for Smoking Cessation in Black Smokers With HIV: Protocol for a Randomized Controlled Trial

• Published in: JMIR research protocols Vol. 13; p. e52090
• Main Authors: Bizier, Andre, Jones, Arielle, Businelle, Michael, Kezbers, Krista, Hoeppner, Bettina B, Giordano, Thomas P, Thai, Jessica M, Charles, Jacqueline, Montgomery, Audrey, Gallagher, Matthew W, Cheney, Marshall K, Zvolensky, Michael, Garey, Lorra
• Format: Journal Article
• Language: English
• Published: Canada JMIR Publications 24.04.2024
• Subjects: Abstinence; Acquired immune deficiency syndrome; Adult; AIDS; Antiretroviral agents; Anxiety; Black or African American - psychology; Cigarettes; Clinical trials; Cognitive ability; Female; HIV; HIV Infections - psychology; Human immunodeficiency virus; Humans; Intervention; Male; Middle Aged; Mobile Applications; Nicotine; Physiology; Pilot Projects; Protocol; Quality of life; Randomized Controlled Trials as Topic; Review boards; Smartphones; Smokers - psychology; Smoking; Smoking cessation; Smoking Cessation - methods; Smoking Cessation - psychology; Stigma; Telemedicine; anxiety sensitivity; HIV; mobile health; smoking cessation; mobile phone; mHealth; Black; just-in-time adaptive intervention
• ISSN: 1929-0748; 1929-0748
• DOI: 10.2196/52090

Black adults who smoke and have HIV experience immense stressors (eg, racial discrimination and HIV stigma) that impede smoking cessation success and perpetuate smoking-related health disparities. These stressors also place Black adults who smoke and have HIV at an increased risk of elevated interoceptive stress (eg, anxiety and uncomfortable bodily sensations) and smoking to manage symptoms. In turn, this population is more likely to smoke to manage interoceptive stress, which contributes to worse HIV-related outcomes in this group. However, no specialized treatment exists to address smoking cessation, interoceptive stress, and HIV management for Black smokers with HIV. This study aims to test a culturally adapted and novel mobile intervention that targets combustible cigarette smoking, HIV treatment engagement and adherence, and anxiety sensitivity (a proxy for difficulty and responsivity to interoceptive stress) among Black smokers with HIV (ie, Mobile Anxiety Sensitivity Program for Smoking and HIV [MASP+]). Various culturally tailored components of the app are being evaluated for their ability to help users quit smoking, manage physiological stress, and improve health care management. This study is a pilot randomized controlled trial in which Black combustible cigarette smokers with HIV (N=72) are being recruited and randomly assigned to use either (1) the National Cancer Institute's QuitGuide app or (2) MASP+. Study procedures include a web-based prescreener; active intervention period for 6 weeks; smartphone-based assessments, including daily app-based ecological momentary assessments for 6 weeks (4 ecological momentary assessments each day); a video-based qualitative interview using Zoom Video Communications software at week 6 for participants in all study conditions; and smartphone-based follow-up assessments at 0, 1, 2 (quit date), 3, 4, 5, 6, and 28 weeks postbaseline (26 weeks postquitting date). Primary outcomes include biochemically verified 7-day point prevalence of abstinence, HIV-related quality of life, use of antiretroviral therapy, and HIV care appointment adherence at 26 weeks postquitting date. Qualitative data are also being collected and assessed to obtain feedback that will guide further tailoring of app content and evaluation of efficacy. The results of this study will determine whether the MASP+ app serves as a successful aid for combustible cigarette smoking cessation, HIV treatment engagement, and physiological stress outcomes among Black people with HIV infection. If successful, this study will provide evidence for the efficacy of a new means of addressing major mental and physical health difficulties for this high-risk population. If the results are promising, the data from this study will be used to update and tailor the MASP+ app for testing in a fully powered randomized controlled trial that will evaluate its efficacy in real-world behavioral health and social service settings. ClinicalTrials.gov NCT05709002; https://clinicaltrials.gov/study/NCT05709002. PRR1-10.2196/52090.